[go: up one dir, main page]

MX2024010450A - Conjugado que consiste de o que comprende al menos un beta-glucano o un manano. - Google Patents

Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.

Info

Publication number
MX2024010450A
MX2024010450A MX2024010450A MX2024010450A MX2024010450A MX 2024010450 A MX2024010450 A MX 2024010450A MX 2024010450 A MX2024010450 A MX 2024010450A MX 2024010450 A MX2024010450 A MX 2024010450A MX 2024010450 A MX2024010450 A MX 2024010450A
Authority
MX
Mexico
Prior art keywords
mannan
glucan
conjugate consisting
cell
conjugate
Prior art date
Application number
MX2024010450A
Other languages
English (en)
Inventor
Markus Mandler
Sabine Schmidhuber
Achim Schneeberger
Carola Wolber
Original Assignee
Tridem Bioscience Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tridem Bioscience Gmbh & Co Kg filed Critical Tridem Bioscience Gmbh & Co Kg
Publication of MX2024010450A publication Critical patent/MX2024010450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de ß- glucanos o manano como adyuvantes polisacáridos de lectina tipo C (CLEC) para polipéptidos de epítopos de células B o T de alfa sinucleína.
MX2024010450A 2022-02-28 2023-02-28 Conjugado que consiste de o que comprende al menos un beta-glucano o un manano. MX2024010450A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22159194 2022-02-28
EP22191217 2022-08-19
PCT/EP2023/055022 WO2023161527A1 (en) 2022-02-28 2023-02-28 A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Publications (1)

Publication Number Publication Date
MX2024010450A true MX2024010450A (es) 2024-09-18

Family

ID=85383015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010450A MX2024010450A (es) 2022-02-28 2023-02-28 Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.

Country Status (9)

Country Link
US (1) US20250186596A1 (es)
EP (1) EP4486388A1 (es)
JP (1) JP2025507875A (es)
KR (1) KR20240153600A (es)
CN (1) CN119053345A (es)
AU (1) AU2023225283A1 (es)
MX (1) MX2024010450A (es)
TW (1) TW202402327A (es)
WO (1) WO2023161527A1 (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590181A (en) 1982-12-20 1986-05-20 Board Of Regents Of The University Of Nebraska Synthetic immunoregulators and methods of use and preparation
PT1284998E (pt) 2000-05-22 2005-06-30 Univ New York Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004012657A2 (en) 2002-08-01 2004-02-12 Immusonic, Inc. Beta-glucan containing composites, methods for manufacturing and for using such composites
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
PT2227248E (pt) 2007-11-26 2014-08-27 Novartis Ag Glucanos com adjuvante
US20090169549A1 (en) 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
EP2887955B1 (en) 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
AU2016209337A1 (en) 2015-01-20 2017-07-13 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
BR112019026707A2 (pt) 2017-06-16 2020-06-30 United Neuroscience imunógenos de peptídeo da extremidade c-terminal da proteína alfa-sinucleína e formulações dos mesmos para o tratamento de sinucleinopatias
JP6410162B1 (ja) 2017-07-24 2018-10-24 有限会社 波多野巌松堂書店 運転支援装置、運転支援方法およびプログラム
CN111514286B (zh) 2020-04-01 2022-03-08 中国科学院过程工程研究所 一种寨卡病毒e蛋白结合疫苗及其制备方法
EP4153210A4 (en) 2020-05-19 2024-11-13 Othair Prothena Limited MULTIPLE EPITOPE VACCINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP2023541671A (ja) 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
CN116438191A (zh) 2020-09-18 2023-07-14 欧萨尔普罗席纳有限公司 治疗阿尔茨海默病之多表位疫苗
CN113616799B (zh) 2021-07-13 2023-08-29 中国科学院长春应用化学研究所 一种疫苗载体、其制备方法及应用

Also Published As

Publication number Publication date
WO2023161527A1 (en) 2023-08-31
US20250186596A1 (en) 2025-06-12
CN119053345A (zh) 2024-11-29
EP4486388A1 (en) 2025-01-08
TW202402327A (zh) 2024-01-16
AU2023225283A1 (en) 2024-08-22
JP2025507875A (ja) 2025-03-21
KR20240153600A (ko) 2024-10-23

Similar Documents

Publication Publication Date Title
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2021006181A (es) Una capsula de bebida.
EP4048487C0 (en) MECHANICAL ARM JOINT
EP4483959A3 (en) Novel peptide compound or pharmaceutically acceptable salt thereof
GB2604909B (en) Subsea foundations
MX2024010450A (es) Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.
AU2017277072A1 (en) Subsea foundations
NZ780983A (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX366418B (es) Papel tisu crepado suave.
FR3035085B1 (fr) Capsule biodegradable et son procede de fabrication
CR20200652A (es) Compuestos que aumentan la actividad del proteosoma
MX2024010451A (es) Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.
CA203705S (en) Chair back
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
CN106153245A8 (zh) 水泵专用压力变送器
MD4588B1 (ro) Compoziţii ce conţin compuşi de tiacumicină
NO20211139A1 (en) Through tubing acoustic measurements
ZA202106874B (en) Nonhormonal unisex contraceptives
CA197996S (en) Digital canister gauge
PH12022550266A1 (en) A method for preparing ivosidenib and an intermediate thereof
EA202192274A1 (ru) Смазка для использования при горячей обработке металлов давлением
TWD211988S (zh) 管夾
PH12020550954B1 (en) Solder alloy and solder joint
PH12019502852A1 (en) Novel compounds activating the nrf2 pathway
WO2020159458A3 (en) Coffee machine with water tank